1. Novel JAK‐1 inhibitor upadacitinib as a possible treatment for refractory SAPHO syndrome: A case report.
- Author
-
Ma, Mingwei, Lu, Siyi, Hou, Xiujuan, and Li, Chen
- Subjects
- *
SYNDROMES , *ANTINEUTROPHIL cytoplasmic antibodies - Abstract
The commonly used criteria for SAPHO syndrome were proposed by Kahn in 1997 and revised in 2003:[1] (1) bone-joint involvement associated with PPP and psoriasis vulgaris; (2) bone-joint involvement associated with SA; (3) isolated sterile hyperostosis/osteitis; and (4) chronic recurrent multifocal osteomyelitis (children). Upadacitinib effectively relieved bone pain and skin damage in patients, and no significant adverse effects were found; thus, it may be a potential treatment option for SAPHO syndrome. Keywords: autoinflammatory disease; SAPHO syndrome; treatment option; upadacitinib EN autoinflammatory disease SAPHO syndrome treatment option upadacitinib 2335 2337 3 11/03/23 20231101 NES 231101 SAPHO syndrome (synovitis, acne, pustulosis, hyperostosis, osteitis) is a rare autoinflammatory disease which may manifest clinically as aseptic osteomyelitis and aseptic joint inflammation, with or without cutaneous manifestations.[1] Osteoarticular symptoms occur mainly in the anterior chest wall (ACW) and may also involve the spine and peripheral joints. [Extracted from the article]
- Published
- 2023
- Full Text
- View/download PDF